Attend this online event to hear about projects in the Longevity Global Community. Longevity Global is a non-profit. We host events for our curated community of longevity researchers, investors, and entrepreneurs. These monthly events include research talks, networking events, hikes, and our annual finale event, the Longevity Summit at the Buck Institute for Research on Aging. We also connect virtually on Slack. You can apply to join us here.
At this event there will be 10 minute presentations followed by questions from the audience. Presentations can be startup pitches or projects that people are working on. Folks presenting should feel free to make any asks they may have, from funding, to hiring, finding teammates, or resources.
1. Gino Cortopassi, CEO of Beiwe Pharma
Novel Selective non-Rapalog mTORC1 inhibitors extend longevity
mTORC1 is the single most-validated target in longevity. The mTORC1-inhibitor Rapamycin extends longevity in yeasts, worms, flies, and mice (Lamming et al. 2013). Rapamycin dose-dependently extends longevity in mice (Miller et al. 2014). Using novel technology we identified the first non-Rapalog mTORC1-specific inhibitor Meclizine (Allen et al. 2018). Meclizine has been dosed since 1955 in millions of humans as anti-vertigo and anti-nausea medication, with a lower side-effect profile than rapamycin. Some of Rapamycin's non-longevity negative side effects are thought to result from its non-specific inhibition of mTORC2 (Lamming et al. 2013). We observe that Meclizine is much more specific than rapamycin, with a 100-fold ratio of mTORC1/mTORC2 selectivity, much superior to rapamycin. We propose this selectivity results from engaging the mTOR target at a different site than Rapalogs. We nominated Meclizine for longevity testing within NIA's Interventions Testing Program (ITP) in 2018, Meclizine extends longevity in male mice, (Harrison et al., submitted). In addition to Meclizine we have identified other chemical scaffolds that inhibit mTORC1 potently and selectively. In Summary, Beiwe has identified the first non-rapalog mTORC1 inhibitors that extend longevity. These appear to bind mTOR at a distinct site than rapalogs, and are much more mTORC1-specific than rapamycin, and have a lower side-effect profile than rapamycin. Beiwe is optimizing these molecules for maximal potency and reduced side-effect profiles to test as Healthy Aging or Longevity therapeutics.
2. Paolo Costa, CEO and Founder, Biolumen, Inc.
MonchMonch the micro-sponge that monches the calories
- MonchMonch (our current "beta", launching October 2023)...the micro-sponge that monches the calories; described by the ex-CSO of Mars as “THE HOLY GRAIL OF NUTRITION".
- Today’s food tastes good...but it’s not good for your health. Our 100% natural "super fiber" makes food healthier, whilst maintaining the same taste.
- Higher dietary fiber content correlates with a reduction in chronic disease. We aim to enable people to live healthier, happier and hence "longer" lives, without the need for diet restrictions.
3. Codi Gharagouzloo, CEO and Co-founder, Imaginostics
Imaginostics is creating the next generation of precision medicine diagnostic tools for clinicians and drug developers to transform personalized healthcare, accelerate drug development, and fight aging.
If you would like to pitch at an event, you can apply by filling out this short form. All stages of projects are welcome. You must be a Longevity Global member to pitch. You can apply to join us here.
Follow us on the platform formerly know as Twitter @LongevityGL